Arimura, A.; Sakai, K.; Kaneshiro, K.; Morisaki, T.; Hayashi, S.; Mizoguchi, K.; Yamada, M.; Kai, M.; Ono, M.; Nishio, K.;
et al. TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer. Cancers 2024, 16, 1184.
https://doi.org/10.3390/cancers16061184
AMA Style
Arimura A, Sakai K, Kaneshiro K, Morisaki T, Hayashi S, Mizoguchi K, Yamada M, Kai M, Ono M, Nishio K,
et al. TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer. Cancers. 2024; 16(6):1184.
https://doi.org/10.3390/cancers16061184
Chicago/Turabian Style
Arimura, Akiko, Kazuko Sakai, Kazuhisa Kaneshiro, Takafumi Morisaki, Saori Hayashi, Kimihisa Mizoguchi, Mai Yamada, Masaya Kai, Mayumi Ono, Kazuto Nishio,
and et al. 2024. "TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer" Cancers 16, no. 6: 1184.
https://doi.org/10.3390/cancers16061184
APA Style
Arimura, A., Sakai, K., Kaneshiro, K., Morisaki, T., Hayashi, S., Mizoguchi, K., Yamada, M., Kai, M., Ono, M., Nishio, K., Nakamura, M., & Kubo, M.
(2024). TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer. Cancers, 16(6), 1184.
https://doi.org/10.3390/cancers16061184
